LYFGENIA is a gene addition therapy designed to add genetic material to your cells. No donor needed. The LYFGENIA treatment process focuses on you—from pre-treatment to follow-up plan. Need support with LYFGENIA? We can help.

Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. [1][3][4][5]

Lyfgenia is a cell-based gene therapy. Lyfgenia uses a lentiviral vector (gene delivery vehicle) for genetic modification and is approved for the treatment of patients 12 years of age and...

Lyfgenia (lovotibeglogene autotemcel) is a gene therapy that is given as a one-time intravenous suspension to treat adults and children aged 12 years and older who have sickle cell disease (SCD) with a history of vaso-occlusive crises (VOCs).

LYFGENIA is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of...

2024年10月7日 · LYFGENIA is indicated for treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events (VOEs).

Learn more about LYFGENIA, a one-time gene therapy for sickle cell disease designed to allow for the production of anti-sickling hemoglobin for patients 12 years or older. Please see …

Learn how LYFGENIA works at the genetic level—from collecting your blood stem cells to adding new modified cells to your body.

What is LYFGENIA™ and how does it work? LYFGENIA is a one-time gene therapy treatment for people age 12 years or older with sickle cell disease and a history of vaso-occlusive pain crises. It has been found to decrease or eliminate vaso-occlusive pain crises in many people.

2024年3月27日 · Casgevy and Lyfgenia are two new therapies approved by the FDA to treat sickle cell disease. A UCHealth expert explains these gene therapies.